We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lansoprazole: In the Treatment of Gastro-oesophageal Reflux Disease in Children and Adolescents.
- Authors
Croom, Katherine F.; Scott, Lesley J.
- Abstract
▴ Lansoprazole is a proton pump inhibitor that inactivates the H+/K+-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH. ▴ In an open-label, uncontrolled trial in children aged 1–11 years with gastro-oesophageal reflux disease (GORD), treatment with lansoprazole 15 or 30mg (depending on weight) once daily for 8–12 weeks improved symptoms compared with baseline in 76% of patients (47 of 62) based on patient diaries and healed erosive oesophagitis (confirmed endoscopically) in all 27 children who had it at baseline. ▴ In adolescents aged 12–17 years with GORD, 8 weeks’ treatment with lansoprazole 15mg (in 64 patients with nonerosive disease) or 30mg (in 23 patients with erosive oesophagitis) once daily reduced the frequency and severity of symptoms by 63% and 69% compared with baseline, based on patient diaries. In this open-label, uncontrolled trial, 96% of evaluable patients with erosive disease (21 of 22) had mucosal healing by week 8, as confirmed by endoscopy; mucosal healing did not occur after an additional 4 weeks’ treatment in one patient. ▴ Lansoprazole was generally well tolerated in children and adolescents, with the most common treatment-related adverse events being gastrointestinal events and headache.
- Subjects
PROTON pump inhibitors; GASTROESOPHAGEAL reflux; PEDIATRIC therapy; TREATMENT of diseases in teenagers; CLINICAL drug trials; GASTROESOPHAGEAL reflux in children; PHARMACODYNAMICS; DRUG efficacy
- Publication
Drugs, 2005, Vol 65, Issue 15, p2129
- ISSN
0012-6667
- Publication type
Article
- DOI
10.2165/00003495-200565150-00005